The Living Guidelines: STEMI Antiplatelet Agents / Anticoagulants Therapy: Clopidogrel Polling Results for CLASS I Guidelines

Any recommendations found on these pages are for education use only. Wikidoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, Wikidoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class I Guidelines
1. For all post-PCI patients who receive a DES, clopidogrel 75 mg daily should be given for at least 12 months if patients are not at high risk of bleeding. For post-PCI patients receiving a BMS, clopidogrel should be given for a minimum of 1 month and ideally up to 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks). Class I (Level of Evidence: B)

 Antiplatelet Agents / Anticoagulants Therapy: Clopidogrel CLASS I Recommendation 1 should be: CLASS I CLASS IIa CLASS IIb CLASS III

2. For all STEMI patients not undergoing stenting (medical therapy alone or PTCA without stenting), treatment with clopidogrel should continue for at least 14 days. Class I (Level of Evidence: B)

 Antiplatelet Agents / Anticoagulants Therapy: Clopidogrel CLASS I Recommendation 2 should be: CLASS I CLASS IIa CLASS IIb CLASS III